Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
78
ALGS Quote, Financials, Valuation and Earnings
Last price:
$10.64
Seasonality move
:
-0.28%
Day range:
$9.84 - $10.26
52-week range:
$3.76 - $46.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
33.71x
P/B ratio:
0.86x
Volume:
33.8K
Avg. volume:
81.5K
1-year change:
-64.28%
Market cap:
$61.5M
Revenue:
$3.9M
EPS (TTM):
-$19.76
Analysts' Opinion
-
Consensus RatingAligos Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $80.25, Aligos Therapeutics, Inc. has an estimated upside of 703.3% from its current price of $9.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $36.00 representing 100% downside risk from its current price of $9.99.
Fair Value
-
According to the consensus of 3 analysts, Aligos Therapeutics, Inc. has 703.3% upside to fair value with a price target of $80.25 per share.
ALGS vs. S&P 500
-
Over the past 5 trading days, Aligos Therapeutics, Inc. has overperformed the S&P 500 by 3.96% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Aligos Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aligos Therapeutics, Inc. revenues have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter Aligos Therapeutics, Inc. reported revenues of $741K.
Earnings Growth
-
Aligos Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Aligos Therapeutics, Inc. reported earnings per share of -$3.04.
Enterprise value:
-31.7M
EV / Invested capital:
-0.41x
Price / LTM sales:
33.71x
EV / EBIT:
--
EV / Revenue:
-11.97x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
0.40x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.3M
Return On Assets:
-77.83%
Net Income Margin (TTM):
-3267.65%
Return On Equity:
-138.89%
Return On Invested Capital:
-123.66%
Operating Margin:
-3827.4%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $16.4M | $6M | $2.6M | $1.3M | $741K | |
| Gross Profit | $13.2M | $3.3M | $1.3M | $602K | $521K | |
| Operating Income | -$84.8M | -$94.6M | -$86.7M | -$20.1M | -$28.4M | |
| EBITDA | -$81.6M | -$91.9M | -$85.4M | -$19.5M | -$28.1M | |
| Diluted EPS | -- | -$13.35 | -$19.76 | -$3.07 | -$3.04 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $248.7M | $150.1M | $74.6M | $79.8M | $103.4M | |
| Total Assets | $263.1M | $164.1M | $85.9M | $88.4M | $109.8M | |
| Current Liabilities | $34.8M | $30.5M | $22.5M | $21M | $22M | |
| Total Liabilities | $46.1M | $42.1M | $31M | $38.3M | $37.9M | |
| Total Equity | $217M | $122M | $54.8M | $50.1M | $71.8M | |
| Total Debt | $12.4M | $10M | $8.6M | $5.7M | $2.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$73.1M | -$85M | -$79.2M | -$20.1M | -$24.3M | |
| Cash From Investing | $56.6M | -$38.3M | -$15.8M | $10.4M | $47.7M | |
| Cash From Financing | $513K | $88.2M | $101.6M | -$4K | -$53K | |
| Free Cash Flow | -$73.2M | -$85.1M | -$79.5M | -$20.1M | -$24.5M | |
ALGS
Sector
Market Cap
$61.5M
$28.5M
Price % of 52-Week High
21.35%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-167.33%
-1.33%
1-Year Price Total Return
-64.28%
-20.32%
Beta (5-Year)
2.743
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$9.70
200-day SMA
Buy
Level
$8.60
Bollinger Bands (100)
Buy
Level
7.89 - 10.43
Chaikin Money Flow
Buy
Level
154.1K
20-day SMA
Buy
Level
$8.38
Relative Strength Index (RSI14)
Buy
Level
62.97
ADX Line
Buy
Level
23.55
Williams %R
Sell
Level
-12.0703
50-day SMA
Buy
Level
$9.01
MACD (12, 26)
Buy
Level
0.40
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
5.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-14.4905)
Sell
CA Score
(Annual)
Level (-5.025)
Buy
Beneish M-Score
(Annual)
Level (-6.9372)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (11.3132)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, ALGS has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ALGS average analyst price target in the past 3 months is $80.25.
-
Where Will Aligos Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aligos Therapeutics, Inc. share price will rise to $80.25 per share over the next 12 months.
-
What Do Analysts Say About Aligos Therapeutics, Inc.?
Analysts are divided on their view about Aligos Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aligos Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $36.00.
-
What Is Aligos Therapeutics, Inc.'s Price Target?
The price target for Aligos Therapeutics, Inc. over the next 1-year time period is forecast to be $80.25 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ALGS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aligos Therapeutics, Inc. is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALGS?
You can purchase shares of Aligos Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aligos Therapeutics, Inc. shares.
-
What Is The Aligos Therapeutics, Inc. Share Price Today?
Aligos Therapeutics, Inc. was last trading at $10.64 per share. This represents the most recent stock quote for Aligos Therapeutics, Inc.. Yesterday, Aligos Therapeutics, Inc. closed at $9.99 per share.
-
How To Buy Aligos Therapeutics, Inc. Stock Online?
In order to purchase Aligos Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ALGS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ALGS
Sector
P/E ratio
--
23.75x
PEG ratio
-0.01x
-0.01x
P/B ratio
0.86x
1.83x
Price / LTM sales
33.71x
1.60x
Growth Metrics
ALGS
Sector
Revenue growth
-41.61%
4.85%
Earnings growth
0.95%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$2.01
-$0.20
Profitability
ALGS
Sector
Profitability FY 2024
$1.3M
$3.6M
Return on invested capital
-123.66%
-30.98%
Return on assets
-77.83%
-27.62%
Return on equity
-138.89%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
9
Estimated Next Earnings Date
Feb
5
Balance Sheet
ALGS
Sector
Total cash
$99.2M
$27.2M
Short term investments
$19.9M
$25.7M
Total assets
$71.9M
$79.7M
Long term debt
$2.5M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 66.41% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.56% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.46% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
